慢性丙型肝炎患者在接受干扰素联合利巴韦林治疗期间的视网膜病变。
Retinopathy in chronic hepatitis C patients during interferon treatment with ribavirin.
作者信息
Jain K, Lam W C, Waheeb S, Thai Q, Heathcote J
机构信息
Department of Ophthalmology, University Health Network, Toronto Western Hospital, University of Toronto, Ontario, Canada.
出版信息
Br J Ophthalmol. 2001 Oct;85(10):1171-3. doi: 10.1136/bjo.85.10.1171.
Abstract
AIM
To assess the ocular effect of interferon alfa 2b prescribed with ribavirin in patients undergoing therapy for chronic hepatitis C.
METHODS
19 patients with chronic hepatitis C who satisfied the follow up criteria were assessed for ocular complications using slit lamp biomicroscopy and indirect ophthalmoscopy before, during, and after the treatment at regular intervals.
RESULTS
8/19 patients, while on treatment, developed an asymptomatic retinopathy. Among these 3/8 were relapsers and 5/9 were non-responders to interferon monotherapy. All retinal changes faded, often while the patients continued the therapy. There was no significant association in occurrence of retinopathy with haematological and/or biochemical changes.
CONCLUSION
Retinopathy was more common in interferon monotherapy non-responders than relapsers when treated with interferon alfa 2b with the addition of ribavirin. The changes were transient, disappearing while the patients were still being treated.
摘要
目的
评估在接受慢性丙型肝炎治疗的患者中，联合利巴韦林使用干扰素α2b的眼部效应。
方法
19例符合随访标准的慢性丙型肝炎患者，在治疗前、治疗期间和治疗后定期使用裂隙灯生物显微镜检查和间接检眼镜检查评估眼部并发症。
结果
19例患者中有8例在治疗期间出现无症状性视网膜病变。其中，8例中的3例为复发者，9例中的5例对干扰素单药治疗无反应。所有视网膜病变均消退，通常在患者继续治疗期间消退。视网膜病变的发生与血液学和/或生化变化无显著关联。
结论
在联合利巴韦林使用干扰素α2b治疗时，视网膜病变在干扰素单药治疗无反应者中比复发者更常见。这些变化是短暂的，在患者仍在接受治疗时消失。
相似文献
1
Retinopathy in chronic hepatitis C patients during interferon treatment with ribavirin.慢性丙型肝炎患者在接受干扰素联合利巴韦林治疗期间的视网膜病变。
Br J Ophthalmol. 2001 Oct;85(10):1171-3. doi: 10.1136/bjo.85.10.1171.
2
Risk factors for retinopathy associated with interferon alpha-2b and ribavirin combination therapy in patients with chronic hepatitis C.慢性丙型肝炎患者中与干扰素α-2b和利巴韦林联合治疗相关的视网膜病变的危险因素。
World J Gastroenterol. 2006 Jun 21;12(23):3756-9. doi: 10.3748/wjg.v12.i23.3756.
3
Posterior segment complications in patients with hepatitis C treated with interferon and ribavirin.接受干扰素和利巴韦林治疗的丙型肝炎患者的后段并发症
Ophthalmology. 2003 Feb;110(2):437-42. doi: 10.1016/S0161-6420(02)01741-4.
4
Is screening for interferon retinopathy in hepatitis C justified?丙型肝炎中干扰素视网膜病变的筛查是否合理？
Br J Ophthalmol. 2004 Dec;88(12):1518-20. doi: 10.1136/bjo.2004.043968.
5
[Retinopathy during interferon treatment in combination with ribavirin for chronic hepatitis C].[慢性丙型肝炎患者在干扰素联合利巴韦林治疗期间的视网膜病变]
Nippon Ganka Gakkai Zasshi. 2005 Nov;109(11):748-52.
6
Combination of "low-dose" ribavirin and interferon alfa-2a therapy followed by interferon alfa-2a monotherapy in chronic HCV-infected non-responders and relapsers after interferon alfa-2a monotherapy.“低剂量”利巴韦林与干扰素α-2a联合治疗，继以干扰素α-2a单药治疗用于慢性丙型肝炎病毒感染患者，这些患者在接受干扰素α-2a单药治疗后无应答或复发。
World J Gastroenterol. 2001 Apr;7(2):222-7. doi: 10.3748/wjg.v7.i2.222.
7
[Pegylated interferon and ribavirin associated retinopathy in patients with hepatitis C].丙型肝炎患者聚乙二醇干扰素和利巴韦林相关视网膜病变
Arch Soc Esp Oftalmol. 2011 Jun;86(6):193-5. doi: 10.1016/j.oftal.2010.12.015. Epub 2011 Apr 29.
8
Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.干扰素α-2b单独或联合利巴韦林作为慢性丙型肝炎的初始治疗。肝炎介入治疗组。
N Engl J Med. 1998 Nov 19;339(21):1485-92. doi: 10.1056/NEJM199811193392101.
9
Hepatitis C: a review of diagnosis, management, and ocular complications from treatment.丙型肝炎：治疗的诊断、管理及眼部并发症综述
Optometry. 2003 Aug;74(8):517-23.
10
Ribavirin with or without alpha interferon versus no intervention, placebo or alpha interferon for chronic hepatitis C.利巴韦林联合或不联合α干扰素与不干预、安慰剂或α干扰素治疗慢性丙型肝炎的比较。
Cochrane Database Syst Rev. 2002(1):CD002234. doi: 10.1002/14651858.CD002234.
引用本文的文献
1
A Drop in Hemoglobin as an Association with Pegylated Interferon Retinopathy: A Novel Pathophysiology.血红蛋白下降与聚乙二醇化干扰素视网膜病变的关联：一种新的病理生理学。
J Curr Ophthalmol. 2020 Apr 30;32(2):195-198. doi: 10.4103/JOCO.JOCO_103_20. eCollection 2020 Apr-Jun.
2
Interferon-α-induced retinopathy in chronic hepatitis C treatment: summary, considerations, and recommendations.慢性丙型肝炎治疗中干扰素-α 诱导的视网膜病变：总结、考量与建议
Graefes Arch Clin Exp Ophthalmol. 2019 Mar;257(3):447-452. doi: 10.1007/s00417-018-04209-7. Epub 2018 Dec 13.
3
Anti-Nuclear Cytoplasmic Antibody-Associated Vasculitis: A Probable Adverse Effect of Sofosbuvir Treatment in Chronic Hepatitis C Patients.抗核胞浆抗体相关血管炎：索磷布韦治疗慢性丙型肝炎患者可能产生的不良反应。
Hosp Pharm. 2017 Apr;52(4):294-301. doi: 10.1310/hpj5204-294.
4
Increasing risk of cataract in HCV patients receiving anti-HCV therapy: A nationwide cohort study.接受抗丙型肝炎病毒治疗的丙型肝炎患者患白内障风险增加：一项全国性队列研究。
PLoS One. 2017 Mar 6;12(3):e0173125. doi: 10.1371/journal.pone.0173125. eCollection 2017.
5
The efficacy of intravitreal interferon alpha-2b for the treatment of experimental endotoxin-induced uveitis.玻璃体内注射干扰素α-2b治疗实验性内毒素诱导性葡萄膜炎的疗效
Indian J Ophthalmol. 2016 May;64(5):376-81. doi: 10.4103/0301-4738.185605.
6
Ophthalmological side effects of interferon therapy of chronic hepatitis C.慢性丙型肝炎干扰素治疗的眼科副作用
Hepatobiliary Surg Nutr. 2016 Jun;5(3):209-16. doi: 10.21037/hbsn.2015.12.14.
7
Interferon-associated retinopathy risk in patients with diabetes and hypertensive hepatitis C.糖尿病合并高血压丙型肝炎患者的干扰素相关视网膜病变风险
World J Gastroenterol. 2014 Jun 21;20(23):7505-13. doi: 10.3748/wjg.v20.i23.7505.
8
Ophthalmologic complications of antiviral therapy in hepatitis C treatment.丙型肝炎治疗中抗病毒治疗的眼科并发症。
World J Gastroenterol. 2013 Dec 7;19(45):8227-37. doi: 10.3748/wjg.v19.i45.8227.
9
Pegylated interferon-associated severe retinopathy in a patient with chronic hepatitis.一名慢性肝炎患者出现聚乙二醇化干扰素相关的严重视网膜病变。
Korean J Ophthalmol. 2012 Apr;26(2):147-50. doi: 10.3341/kjo.2012.26.2.147. Epub 2012 Mar 22.
10
[Combined retinal artery and vein occlusions associated with interferon beta therapy].[与干扰素β治疗相关的视网膜动静脉联合阻塞]
Ophthalmologe. 2012 Jan;109(1):71-5. doi: 10.1007/s00347-011-2448-0.
本文引用的文献
1
Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group.单用干扰素α-2b或联合利巴韦林治疗慢性丙型肝炎复发。国际肝炎介入治疗组
N Engl J Med. 1998 Nov 19;339(21):1493-9. doi: 10.1056/NEJM199811193392102.
2
Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.干扰素α-2b单独或联合利巴韦林作为慢性丙型肝炎的初始治疗。肝炎介入治疗组。
N Engl J Med. 1998 Nov 19;339(21):1485-92. doi: 10.1056/NEJM199811193392101.
3
Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT).干扰素α2b联合利巴韦林治疗48周或24周与干扰素α2b联合安慰剂治疗48周用于慢性丙型肝炎病毒感染的随机试验。国际肝炎介入治疗组（IHIT）。
Lancet. 1998 Oct 31;352(9138):1426-32. doi: 10.1016/s0140-6736(98)07124-4.
4
Interferon associated retinopathy.干扰素相关性视网膜病变
Br J Ophthalmol. 1998 Mar;82(3):323-5. doi: 10.1136/bjo.82.3.323.
5
Clinical characteristics of hepatitis C virus-associated retinopathy.丙型肝炎病毒相关性视网膜病变的临床特征。
Jpn J Ophthalmol. 1995;39(4):411-9.
6
Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C.利巴韦林联合干扰素α治疗慢性丙型肝炎的长期疗效
Gastroenterology. 1996 Nov;111(5):1307-12. doi: 10.1053/gast.1996.v111.pm8898645.
7
Side effects of high-dose interferon therapy for chronic hepatitis C.
J Hepatol. 1996 Sep;25(3):283-91. doi: 10.1016/s0168-8278(96)80113-9.
8
[Ribavirin treatment in patients with chronic hepatitis C refractory to interferon-alpha].
Gastroenterol Hepatol. 1996 May;19(5):243-6.
9
10
Zotero 插件